Ultragenyx Pharma (RARE) Tops Q4 EPS by 18c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.52), $0.18 better than the analyst estimate of ($1.70). Revenue for the quarter came in at $127.39 million versus the consensus estimate of $119.38 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02
• Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c